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Background: In non-cystic ﬁbrosis (CF) subjects, the disposition index (DI) is a strong predictor of the development of type 2 diabetes. CF subjects
are at high risk of diabetes. We hypothesized that DI would be reduced in CF patients with normal glucose tolerance (NGT), indicating β-cell
dysfunction, and DI would worsen with progression from CF with NGT to CF-related diabetes (CFRD).
Methods: This was a cross-sectional study in 39 CF patients and 21 healthy controls (Con) who underwent oral glucose tolerance test (OGTT).
Insulin sensitivity was estimated as (1/fasting insulin) and insulin secretion as (Δinsulin 0–30 min/Δglucose 0–30 min). DI was calculated as
(insulin sensitivity) × (insulin secretion).
Results: Among CF subjects, 14 had NGT, 20 had prediabetes and 5 had CFRD. Among the controls, 14 had NGT and 7 had prediabetes. DI was
signiﬁcantly lower in CF-NGT compared to Con-NGT (p = 0.0035). DI was also lower in CFRD compared to CF-NGT (p = 0.025). There were
no signiﬁcant relationships in the CF groups between DI and age, BMI, percent body fat or FEV1.
Conclusion: β-Cell function as measured by DI is reduced in CF patients compared to non-CF controls—even in CF-NGT—and is decreased
further in CF patients with diabetes. If DI proves to be a predictor of the development of CFRD in larger studies, then it could be used to identify
CF patients who are at particularly high risk, allowing early interventions aimed to delay or prevent CFRD.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Diabetes; OGTT; Beta-cell function1. Introduction
Cystic fibrosis-related diabetes (CFRD) is one of the most
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50% of adults with CF [1]. CFRD is associated with increased
morbidity and mortality, worse nutritional status and higher
rates of respiratory exacerbations requiring hospitalization—
which contribute to the accelerated decline in lung function in
these patients [2–5]. The overall mortality rate per 100 person-
years is 3.5 ± 0.6 in patients with CFRD, compared to 1.0 ± 0.2
per 100 person-years for CF patients without CFRD [1]. Lang et al.
have shown that in patients with CF, prediabetes starts 4 to 6 years
before overt CFRD presents. CF patients with prediabetes exhibit
a lower BMI andmore rapid decline in lung function compared to
CF patients with normal glucose tolerance (NGT) [6]. CFRD isll rights reserved.
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thought to decrease morbidity and mortality [7].
It is recommended that screening for CFRD should begin by
the age of 10 years, using oral glucose tolerance tests (OGTTs)
[8]. However, some CF patients with normal fasting and 2-h
glucose levels have elevated serum glucose levels and higher
glucose readings on continuous glucose monitoring in the middle
of the OGTT [9], and those patients with elevation in 1-h glucose
levels are thought to be at high risk of worse pulmonary disease
[10]. Such observations highlight the need for a measurement that
can predict the development of prediabetes and diabetes in CF
subjects when their OGTTs are still normal since early treatment
might help to delay or prevent the development of morbidities.
We sought to examine the disposition index (DI), a measure
of β-cell function adjusted for insulin sensitivity, in a cohort of
CF patients and healthy controls. In non-CF subjects, there is a
hyperbolic relationship between early insulin secretion and insulin
action [11]. On the basis of this hyperbolic relationship, the
product of these two variables can be calculated to yield the DI,
which can be understood as the ability of β-cells to compensate
for alterations in insulin sensitivity. Utzschneider et al. [12]
have shown that the baseline DI in non-CF subjects who later
developed type 2 diabetes was significantly lower than that in
subjects who remained without diabetes.
Based on this information, we first determined if the
relationship between insulin sensitivity and insulin secretion
followed a hyperbolic pattern, and thenwe estimated the DI in our
CF subjects and healthy controls. We then tested two hypotheses:
(i) the DI will be reduced in CF patients with NGT, indicating
β-cell dysfunction despite normal glucose values, and (ii) the DI
will be lower in CFRD and CF prediabetes patients compared
to CF patients with NGT, indicating worsening of DI with
progression to diabetes.We also examined the utility of the 30-min
OGTT glucose level—as a potential proxy for DI—to identify the
development of β-cell dysfunction in patients with CF.
2. Patients and methods
Thirty-nine CF subjects, 16 years and older, who were
clinically stable with no pulmonary exacerbations within 6 weeks
of study and who had no current or recent oral corticosteroid use,
were recruited from the Emory CF Clinic after providing informed
consent. Healthy controls consisted of 21 subjects, 16 years and
older, with no chronic illness requiring prescription medications,
no acute illness within 3 weeks of study and no known history of
diabetes or an abnormal glucose tolerance test. The study was
approved by the Emory University Institutional Review Board.
All subjects fasted starting the evening before the test at 10:00
p.m. with nothing to eat or drink except for water. Subjects were
admitted to the Atlanta Clinical and Translational Science Institute
(ACTSI) research unit in the morning. Height and weight were
measured, and percent body fat was assessed with air displace-
ment plethysmography (BOD POD®Body Composition System,
COSMED USA, Inc.). Spirometry was performed in CF subjects
using the American Thoracic Society standards and percent
predicted forced expired volume in 1 second (FEV1) was
calculated in order to determine if there was any correlationbetween DI and lung function. Then an OGTT was performed
with administration of glucose 1.75 mg/kg body weight, to a
maximum of 75 grams. Blood was drawn at 0, 30 min and 2 h for
measurement of glucose and insulin.
Using the 2003 American Diabetes Association criteria [13],
subjects were categorized as having normal glucose tolerance
(fasting plasma glucose [FPG] b 5.56 mmol/l and 2-h plasma
glucose b 7.78 mmol/l), prediabetes (impaired fasting glucose
[IFG] with FPG 5.56–6.99 mmol/l, and/or impaired glucose
tolerance [IGT] with 2-h plasma glucose 7.78–11.10 mmol/l)
or diabetes (FPG N7.0 mmol/l and/or 2-h plasma glucose N
11.11 mmol/l).
Glucose and insulin assays were performed by Cardiovascular
Specialty Laboratories in Atlanta, Georgia. Insulin was measured
using Sekisui Diagnostics immunoturbidimetric assay.
Insulin sensitivity was calculated as 1/fasting insulin. Insulin
secretion was calculated as the ratio of the change in insulin to
the change in glucose from 0 to 30 min (ΔI0–30/ΔG0–30).
Disposition index was calculated as 1/fasting insulin multiplied
by (ΔI 0–30/ΔG 0–30).
To determine whether there was a hyperbolic relationship
between insulin sensitivity and insulin secretion (insulin
sensitivity × insulin secretion = constant) within each group,
we used linear regression analysis to estimate ln(insulin sensitiv-
ity) as a linear function of ln(insulin secretion). A hyperbolic
relationship was presumed if the 95% CI of the slope included −1.
The Kruskal–Wallis test was used to compare continuous
variables and the Fisher's exact test was performed to compare
categorical variables among the CF and control groups, namely,
Con-NGT, Con-prediabetes, CF-NGT, CF-prediabetes andCFRD.
Spearman correlation coefficients were calculated between DI
and other continuous variables. The Wilcoxon rank sum test
was used to determine whether DI was different between males
and females and between pairs of patient groups. Discrimination
of glucose tolerance status by the OGTT 30 min glucose level
compared with DI was evaluated by receiver operating
characteristic (ROC) analyses, using identification of diabetes
and normal glucose tolerance as the end points in separate
analyses. Linear regression was also used to investigate
the relationship between DI and other variables after adjusting
for potential confounders. A p-value of b0.05 was considered
statistically significant. Statistical analysis was performed
using R software, version 2.15.2 (R foundation for statistical
computing, Vienna, Austria).
3. Results
The subjects were categorized based on their OGTT results
on the day of the study (Table 1). Among the CF subjects, 14
had NGT, 20 had prediabetes and 5 had CFRD. Among the
controls, 14 subjects had NGT and 7 subjects had previously
unrecognized prediabetes. There was no statistical difference
between the 5 groups in regard to gender, BMI or % fat. There
was a difference in age, with CF-prediabetes and CFRD
subjects being significantly younger than Con-NGT. There was
also a difference in the 30-min glucose values, with all of the
CF groups having significantly higher values than Con-NGT.
Table 1
Characteristics of CF subjects and controls by glucose tolerance category.
Subjects Con-NGT
n = 14
Con-prediabetes
n = 7
CF-NGT
n = 14
CF-prediabetes
n = 20
CFRD
n = 5
p-value b
Age (years) 31.2 ± 7.9 30 ± 10 26.8 ± 7.88 22.8 ± 6.6 22.6 ± 6.61 0.018 c
Gender (women/men) 5/9 4/3 8/6 7/13 3/2 0.56 d
BMI (kg/m2) 24 ± 2.9 24.9 ± 5.3 22.8 ± 3.18 22.4 ± 3.3 22.1 ± 3.1 0.39
Fat % 22.6 ± 7.2 28.3 ± 7.3 26.7 ± 4.85 28.1 ± 5.7 26.7 ± 12.1 0.49
FEV1% 82.9 ± 22 85.6 ± 20.3 86.6 ± 15 0.39
Fasting PG (mmol/l) a 4.9 (0.8) 5.5 (0.14) 4.87 (0.82) 5.4 (1.07) 5.3 (1)
30 min PG (mmol/l) a 7.36 (1.48) 8.25 (0.64) 8.36 (2.46) 8.6 (1.88) 9.5 (1.42) 0.03 e
2-h PG (mmol/l) a 5.66 (1.2) 7.78 (0.19) 5.76 (1.46) 8.4 (1.74) 13.2 (1.85)
Fasting insulin (pmol/l) a 27.78 (3.1) 65.28 ( 29.8) 27.78(17.28) 38.2 (14.4) 27.78(0.69)
PG: plasma glucose. Values are presented as mean ± SD unless otherwise specified.
a Values in median (interquartile range).
b Kruskal–Wallis test.
c Con-NGT vs. CF-prediabetes (p = 0.003). Con-NGT vs. CFRD (p = 0.025).
d Fisher exact test.
e Con-NGT vs. CF-NGT (p = 0.03), Con-NGT vs. CF-prediabetes (p = 0.004), Con-NGT vs. CFRD (p = 0.02).
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relationship between ln(1/fasting insulin) and ln(ΔI0–30/
ΔG0–30) in all groups except the CFRD group (Fig. 1),
suggesting a hyperbolic relationship between insulin sensitivity
and insulin secretion in Con-NGT, Con-prediabetes, CF-NGT,
and CF-prediabetes.Fig. 1. The computed slopes for ln(Insulin secretion) versus ln(Insulin sensitivity) in
The slope and confidence interval (CI) for each of the groups is as follows. Con-NG
with CI [−1.4689, −0.4707]; CF-NGT: slope −0.0824 with CI [−1.0339, 0.8690]
21.2791 with CI [−35.0945, −7.4637].Based on this hyperbolic relationship, the composite measure
of insulin sensitivity and insulin secretion was calculated to yield
the DI. The insulin sensitivity, insulin secretion and DI results are
shown in Table 2. Based on the Kruskal–Wallis test, there were
significant differences among the 5 groups in insulin secretion
(p b 0.0001) and in DI (p b 0.0001) but no significant differencesthe five groups showing that the slope includes −1 for all groups except CFRD.
T: slope −0.5364 with CI [−1.6383, 0.5655]; Con-prediabetes: slope −0.9698
; CF-prediabetes: slope −0.4622 with CI [−1.2518, 0.3273]; CFRD: slope −
Table 2
Insulin sensitivity, insulin secretion and disposition index in all groups.
Con-NGT
n = 14
Con-prediabetes
n = 7
CF-NGT
n =14
CF-prediabetes
n = 20
CFRD
n = 5
p-value for
all groups a
p-value for
CF only a
Insulin sensitivity (pM−1) 0.0327 (0.0095) 0.0263 (0.0171) 0.0350 (0.0124) 0.0276 (0.0067) 0.0352 (0.0013) 0.0817 0.064
Insulin secretion (pmol/mmol) 174.60 (222.29) 122.74 (69.36) 49.22 (24.11) 41.43 (18.16) 18.17 (15.79) b0.0001 0.038
Disposition index (mM−1) 5.00 (4.94) 2.41 (0.79) 1.72 (1.10) 1.11 (0.49) 0.63 (0.53) b0.0001 0.053
Values are presented as mean (SD).
a Kruskal–Wallis test.
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5 groups. Based on the Wilcoxon rank sum test, there were
significant differences in DI between Con-NGT and each of the
CF groups, between Con-prediabetes and each of CF-prediabetes
and CFRD, and between CF- NGT and CFRD (Table 3a). In
regard to the 30-min glucose levels, there were only significant
differences between the Con- NGT and each of the CF groups
(Table 3b).
There were no significant relationships in the CF groups
between DI and age, BMI, percent body fat or FEV1. There was
a significant negative correlation between DI and the 30-min
glucose levels in each of Con-NGT, CF-NGT and CFRD
separately and in the 3 CF groups and in all five groups
combined (Supplementary table 1). Metabolic discrimination by
DI vs. the 30-min glucose level was compared by ROC analysis.
To identify NGT, the area under the ROC curve (AUC) for DI
was 0.729, slightly but not significantly greater than the AUC for
the 30-min glucose, 0.681 (p = 0.44). To identify diabetes, the
ROC AUC for DI was 0.858, again slightly but not significantly
greater than the ROC AUC for 30-min glucose, 0.652 (p = 0.06)
(Fig. 3).
4. Discussion
The development of improved measures of glucoregulatory
metabolism is important for the care of patients with CF because
prediabetes and diabetes have a major impact on the course of
the disease, and conventional assessments (HbA1c, fasting and
OGTT 2-h glucose levels) are insensitive to early dysfunction.
Our study shows that compared to non-CF controls with normalFig. 2. The disposition index in controls and CF subjects according to their
glucose tolerance category.glucose tolerance, DI is reduced in patients with CF even when
their glucose tolerance is normal, and it is further decreased in
those with diabetes. Our findings indicate that measurement of DI
may be clinically useful in patients with CF to detect subtle
defects in β-cell function, and identify progression of the disease.
A hyperbolic relationship between insulin sensitivity and
secretion—critical to the rigorous use of DI—has not been
demonstrated previously in patients with CF. After initial
studies with intravenous approaches established the potential
utility of DI assessments in non-CF subjects [14], Kahn et al.
showed that the nature of the relationship between insulin
sensitivity and secretion is consistent with a feedback loop control
system [11]. More recently, Utzschneider et al. have shown that
the relationship also applies to more physiologic, oral glucose
administration and is present not only in subjects with NGT but
also in subjects with prediabetes and diabetes [12], and that DI
measured using an OGTT is predictive of the future development
of diabetes. Our demonstration of the hyperbolic relationship in
our non-CF subjects is consistent with their results, and we have
established that this relationship holds in CF patients as well.
Furthermore, we found that CF subjects demonstrated early
hyperglycemia during the OGTT, as shown by their 30-min
glucose levels that were significantly higher than values in non-CF
controls; 30-min glucose levels were even elevated in CF patients
with NGT. Previous studies found that OGTTs and HbA1c
measurements may fail to detect early glucose abnormalities in CF
subjects. Dobson et al. reported that glycemic status measured by
both the combined response at 30, 60 and 90 min and continuous
glucose monitoring (CGM) during an OGTT is higher in CF
subjects than in controls who have similar HbA1c, fasting and 2-h
glucose values [9]. Moreau et al. reported that in CF subjects,Table 3
The p-values using the Wilcoxon rank sum test for testing differences in DI (a)
and the 30-min glucose levels (b) between pairs of groups.
Con-prediabetes CF-NGT CF-prediabetes CFRD
(a)
Con-NGT 0.1718 0.0035* 0.0001* 0.0012*
Con-prediabetes 0.1490 0.0021* 0.0025*
CF-NGT 0.1894 0.0258*
CF-prediabetes 0.0960
(b)
Con-NGT 0.0931 0.0029 ⁎ 0.0048 ⁎ 0.0233 ⁎
Con-prediabetes 0.971 0.455 0.53
CF-NGT 0.391 0.443
CF-prediabetes 0.8384
⁎ p-value b0.05.
Fig. 3. ROC curves for DI and 30-min glucose levels on determination of normal
glucose tolerance (a) and determination of diabetes (b). TPR: true-positive rate;
FPR: false-positive rate.
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least once after a meal in 36% of CF patients with NGT, 52% of
patients with IGT and in all patients with CFRD [15]. In addition,
higher 1-h OGTT glucose levels in CF patients were found to be
associated with an increased risk for future CFRD [16] and
correlated with worse pulmonary function [10]. Similarly, in non-
CF subjects, the 1-h glucose level during the OGTT was shown to
be a strong predictor of future risk for type 2 diabetes [17].
Although 30-min glucose levels have not previously been studied
systematically in patients with CF, such early postprandial/
postchallenge hyperglycemia might reflect underlying defects in
pancreatic beta-cell function, and the findings reviewed above
constitute evidence that it might be a risk factor for the
development of CFRD and deterioration in lung function.
The DI was significantly lower in all the CF groups—even
in CF patients with NGT—compared to non-CF controls. There
was no significant difference in insulin sensitivity between
these groups, which indicates that the defect is mainly in the
inability of β-cells in CF patients to secrete insulin. Although
there have been no previous studies of DI in CF patients, our
findings are consistent with earlier work showing that insulin
secretion is impaired in CF patients even when they have NGT,
while their insulin sensitivity is not affected [18–20]. We found
no correlation between DI and BMI, % fat or lung function inCF subjects. Our CF subjects were also not different from
controls in regard to gender, BMI or % fat, and their mean lung
function was within the normal range. Our sample accordingly
represents stable, well-nourished CF patients in good clinical
condition. The low DI in these patients indicates that the insulin
secretory defect is likely primary in the pathogenesis of CFRD,
and that it declines well before deterioration in clinical status. It
also implies that the defect might be unmasked if insulin
resistance increases, possibly limiting glycemic compensation
in times of illness, infection or during puberty, and resulting in
hyperglycemia.
DI, or possibly 30-min OGTT glucose levels, could
potentially be used to identify the subset of CF subjects who
are at particularly high risk for developing diabetes and perhaps
allow such patients to be targeted for more frequent monitoring
or early intervention. DI was not superior to the 30-min glucose
levels in identifying diabetes or NGT in our ROC analyses, but DI
was superior to 30-min glucose levels in metabolic discrimination
of individual patient groups. Both DI and 30-min glucose
discriminated between con-NGT and all CF groups, but only DI
discriminated CF-NGT from CFRD (Table 3). It is possible that
DI measurement could be used to help predict the subsequent
development of CFRD in CF-NGT patients who are in stable
clinical condition. We found an overlap in the DI values between
controls with NGT and CF with NGT and therefore not all
CF patients may be at increased risk of developing diabetes.
However, there may well be a subset of these CF patients with
NGT andwith a lower DI value that is at increased risk. The cutoff
value for DI below which the risk for developing prediabetes and
diabetes is higher could be determined after conducting a large
prospective trial and following CF patients with NGT over time.
The strengths of our study include the following: (1) the first
study to assess DI in CF patients and compare it to non-CF
controls; (2) the use of a broad range of patient groups that were
physiologically comparable except for CF and glycemic status;
(3) the rigorous assessments of discrimination according to DI
and 30-min glucose levels; and (4) in 2010, the CF Foundation
recommended that an OGTT be done annually as a screen for
CFRD in all CF patients 10 years of age and older. Adding the
insulin assay at two time points during this standard clinically
recommended screening test will be practical and easy to
implement if DI proves to be effective in larger studies. The
limitations to our study include the following: (1) the relatively
small sample size. Our findings including the hyperbolic
relationship between insulin secretion and sensitivity in CF
patients need to be validated in future larger studies. (2) The
regression analysis that we used to demonstrate the hyperbolic
relationship may not account for measurement error in predictors,
noting that it is difficult to correct for such measurement error in
the absence of replicate or validation data. (3) It is a cross-
sectional study. We do not know how DI may change in
individuals as they develop CFRD, and we cannot confirm that it
will predict progression to CFRD. (4) The OGTT measures can
be variable compared with intravenous testing [21] and the
insulin secretion measure that we used (ΔI 0–30/ΔG 0–30) is not
thorough as it includes only two insulin measurements. However,
this measure has been validated in CF patients and found to have
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tolerance testing [22]. The insulin sensitivity measure we used
(1/fasting insulin) has also been validated in non-CF patients and
found to correlate well with insulin sensitivity measured via
glucose clamps [23]. (5) We did not obtain 1 hr glucose values
during the OGTT and thus we are unable to assess if it has a
superior prediction value compared to DI.
In summary, we have found thatβ-cell function as measured by
the DI is reduced in CF patients compared to non-CF controls—
even in CF patients with normal glucose tolerance—and is
further decreased in CF patients with diabetes. The low DI in this
sample of CF patients was due primarily to an insulin secretory
defect that was present despite stable pulmonary disease and
adequate nutritional status. Our findings indicate that in CF
patients with normal glucose tolerance, the underlying insulin
secretion defect might be unmasked during times of acute stress
when insulin resistance increases, possibly resulting in hypergly-
cemia. If DI proves to be a predictor of the development of
prediabetes and CFRD in larger studies, it is possible that it could
be used to identify the subset of CF patients who are at particularly
high risk. This would allow early intervention aimed to preserve
their β-cells and help prevent or delay the development of CFRD
and its associated morbidity and mortality.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.06.004.
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